The Early Start Struggle
Many workers face the significant biological challenge of beginning their day long before sunrise. This isn't a matter of motivation, but a direct conflict
with the body's natural sleep-wake cycle, often leading to what's known as shift work disorder. This condition is characterized by profound sleepiness during waking hours, which can negatively impact concentration, job performance, and crucially, workplace safety. While overnight shifts are often discussed, early morning schedules, typically starting between 3 a.m. and 7 a.m., are far more common. Workers on these shifts often don't identify as 'shift workers' but rather as having an unusually early workday. Nevertheless, they are highly susceptible to the disruptive effects of working against their circadian rhythm, experiencing not only daytime drowsiness but also difficulties sleeping soundly when they finally have the chance to rest.
Solriamfetol's Potential
Addressing this widespread issue, a recent clinical trial conducted by Mass General Brigham has explored a potential solution: solriamfetol (marketed as Sunosi). This medication, already approved for treating excessive sleepiness associated with narcolepsy and obstructive sleep apnea, was investigated for its efficacy in early morning shift workers diagnosed with shift work disorder. Unlike some older wakefulness-promoting drugs, solriamfetol was considered a promising candidate because it promotes alertness for several hours without substantially hindering subsequent sleep. The study, published in NEJM Evidence, aimed to fill a crucial void, as previous research had largely overlooked early morning shift workers, despite their prevalence.
Clinical Trial Design
The study involved 78 participants who were experiencing excessive sleepiness due to their early morning work schedules and met the diagnostic criteria for shift work disorder. These individuals were randomly assigned to one of two groups for a four-week period. One group received solriamfetol on each workday, while the other group was given a placebo. To assess the drug's effectiveness, researchers employed several evaluation methods. Participants underwent objective tests to measure how long they could remain awake in a controlled, dark, and quiet environment during times that corresponded to their usual work hours. Additionally, participants engaged with physicians to report on their subjective experiences and overall daily functioning.
Improved Alertness and Function
The results of the clinical trial demonstrated a significant positive impact of solriamfetol. After four weeks of treatment, the group receiving the medication reported considerably less sleepiness and showed an increased ability to stay awake during simulated work periods. Both the participants and their treating physicians observed notable improvements in their overall functioning, work productivity, and engagement in daily life activities. Senior author Charles A. Czeisler highlighted the clinical significance of these findings, stating that workers were able to maintain alertness throughout a full eight-hour shift. This improvement has profound implications for their performance, safety on the job, and overall quality of life, acknowledging the hidden biological toll many essential shift workers endure.
Future Directions
While this study provides compelling evidence for solriamfetol's effectiveness in early morning shift workers, the researchers acknowledge certain limitations. The trial focused on otherwise healthy adults, and the long-term effects of the medication still require further investigation. Moreover, early morning shift work has historically received less research attention compared to other shift patterns. To build upon these findings, the research team is currently recruiting participants for a follow-up clinical trial. This next phase will specifically examine solriamfetol's effects on individuals working overnight shifts, which could potentially support broader approval for its use in treating shift work disorder across various schedules.
